Shareholders' Equity

9 Months Ended

Sep. 30, 2014

Shareholders' Equity [Abstract]

Shareholders' Equity

Note 6. Shareholders’ Equity

Preferred Stock

The Company has 350,000 shares of preferred stock authorized, none of which are issued or outstanding.

Common Stock

During the nine months ended September 30, 2014, the Company issued the following shares of common stock:

● In January 2014, the Company issued 77,889 shares of common stock in connection with the cashless exercise of 250,000 stock warrants;

● In March 2014, the Company issued 76,932 shares of common stock pursuant to the Lincoln Park facility;

● In April 2014, the Company issued 76,907 shares of common stock pursuant to the Lincoln Park facility;

● In July 2014, the Company issued 76,904 shares of common stock pursuant to the Lincoln Park facility;

● In May 2014, the Company issued 43,067 shares of common stock upon the execution of an agreement to evaluate specific oncology technology;

● In May 2014, the Company issued 29,172 shares of common stock upon the exercise of vested stock options;

● In July 2014, the Company issued 7,500 shares of common stock upon the exercise of vested stock options;

● In August 2014, the Company issued 65,115 shares of common stock with the cashless exercise of 336,081 stock warrants;

● In September 2014, the Company issued 1,849,113 shares of common stock in connection with the Hy BioPharma Acquisition of in process research and develpment.

● In four separate transactions, the Company issued 121,000 shares of common stock as partial consideration for services performed.